# Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation

> **NCT05054478** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 29 (estimated)

## Conditions studied

- Plasma Cell Leukemia

## Interventions

- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT05054478
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2021-10
- **Primary completion:** 2024-06
- **Final completion:** 2028-02
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2021-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05054478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05054478, "Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05054478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*